Status:
COMPLETED
Study of Combination Therapy With SYR-322
Lead Sponsor:
Takeda
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
To determine the efficacy and safety of SYR-322 (alogliptin) 25-mg, once daily (QD), in patients with diabetes when used in combination with insulin.
Eligibility Criteria
Inclusion
- The subject is an outpatient.
- The subject signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
Exclusion
- The subject has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease.
- The subject is considered ineligible for the study for any other reason by the investigator or subinvestigator.
Key Trial Info
Start Date :
February 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT01521962
Start Date
February 1 2012
End Date
March 1 2013
Last Update
November 13 2013
Active Locations (33)
Enter a location and click search to find clinical trials sorted by distance.
1
Aomori, Aomori, Japan
2
Hirosaki-shi, Aomori, Japan
3
Kashiwa-shi, Chiba, Japan
4
Kisarazu-shi, Chiba, Japan